Agenus (AGEN) Shares Active as Glaxo (GSK) Submits Shingrix BLA to U.S. FDA
- Wall Street gains, helped by oil, economic data
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Unusual 11 Mid-Day Movers 12/5: (NVCN) (BCEI) (MEMP) Higher; (GTXI) (CERC) (HDSN) Lower
- Oil hits 16-month high in buying rush after OPEC agreement
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Agenus (NASDAQ: AGEN) shares are up around 6 percent in early trading Monday as GlaxoSmithKline (NYSE: GSK) announced that it submitted a Biologics License Application (BLA) for its candidate shingles vaccine, Shingrix, to the United States Food and Drug Administration (FDA), seeking approval for the prevention of herpes zoster (shingles) in people aged 50 years or over.
In part, the Glaxo press release read:
The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon® adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., MPL and liposomes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Options with increasing volume:PAH TNP WAT RSX EWI DHR JJC HLT
- Volatility and Volume movement
- Stocks with call price movement; TRIP NFLX
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!